

International Public Health University (IPHU)

Day 7 – 12/11/2018

Access to Medicines stream

The day's activities started with the Gopa introducing the topic of Alternative models R&D in the highlight of politics and economics of Innovation & Access by Transnational Pharma companies.

- Problems with the current patent lead model
- Market failure
- Problem of 90/10 i.e. 90% of R&D funds go for diseases that affects 10% of global population
- Unmet needs in the form of new medicines / diagnostics, FDCs, adaptation to local needs
- R&D financing for Neglected Diseases – less involvement of Pharma TNCs
- Guideline building for R&D – Innovation should be delinked from patent lead funding system, instead alternative models should be developed like grants and prizes, advance marketing commitment, open innovation etc
- Financing – philanthropic – questionable
- WHO process (1992) – Evolution from Global Strategy of Paths for Actions (GSOPA) to CEWG report & recommendations, UN High Level Panel on Access to Medicines.
- Scope of Activism – International and National level, Right to Science

Post tea, the groups discussed and finalised their project works and post-lunch made half an hour presentation on the given case studies (including campaign strategies), each followed by discussion on the topics.

- Free Trade Agreements and TRIPS plus provisions that erode the Doha declaration principles
- Flexibilities of Least Developed Countries in the TRIPS framework
- Foreign Direct Investments, Clinical Trials, and Data Exclusivity
- Free Trade Agreements and Patent Linkages that restrict market approvals for generic drug companies
- Compulsory licences and myths surrounding it
- The proposed African Medicines Agency (AMA) and the concerns surrounding it, and proposal to PHM Africa for action.